Cardiac Monitors in California

Since 1986, Jant Pharmacal Corporation has been a leading B2B supplier of point-of-care (POC) diagnostic tests and laboratory instrumentation to U.S. and international healthcare settings. The company operates two primary divisions: POC Division and Lab Division. The POC Division offers CLIA-waived rapid tests and analyzers for use in physicians' offices, clinics, urgent care centers, and hospitals under registered trademarks Accutest, Accustrip, and LipidPlus. Product categories include cardiac testing, colorectal cancer screening, drugs of abuse, hypothyroidism, infectious diseases, pregnancy & fertility, and urinalysis. The Lab Division provides integrated solutions for laboratory optimization, featuring clinical chemistry, hematology, immunoassay, toxicology, urinalysis, and molecular diagnostic systems with reagents and consumables. The company holds GPO supplier contracts with Vizient and Champs, representing over 500,000 members. Additionally, Jant offers laboratory consultation services including financial feasibility assessment, turn-key laboratory setup, CLIA compliance consultation, LCMS method development, and laboratory information system integration.

ACI Medical, LLC is a biomedical engineering firm specializing in non-invasive vascular diagnostic and therapeutic devices for patients with limb- and life-threatening vascular conditions. With over 30 years of experience, the company develops, manufactures, and distributes patented medical devices including the ArtAssist® Arterial Assist Device for peripheral arterial disease, diabetic foot ulcers, and critical limb ischemia; diagnostic tools such as the APG® Air Plethysmograph for venous disease assessment; and compression and augmentation devices like VenaPulse® and UnnaSleeve™. The company operates an FDA-registered contract manufacturing division producing miniature diaphragm pumps for medical and industrial applications, as well as custom plastic injection molding services. ACI Medical devices are available for home use and clinical settings, with strong relationships with VA hospitals nationwide.

QT Medical, Inc. is a medical device manufacturer specializing in portable, wireless, cloud-connected 12-lead ECG systems for hospital-grade cardiac diagnostics and monitoring. Founded in 2013 and based in Diamond Bar, California, the company provides FDA-cleared solutions for both home-use self-monitoring and professional acute care settings. The QT ECG / PCA 500™ platform features pre-positioned sensors (QHeart®), AI-driven computer interpretation, and HIPAA-compliant cloud storage (ECGcloud®). Products are designed for patients from newborns to adults, reducing lead placement time by up to 70% and minimizing common errors such as limb-lead reversal. The company offers integrated mobile applications (iOS, Android, Windows) and cloud-based workflow management. QT Medical also provides Xpress ECG home delivery services and telemedicine-compatible solutions to enable accessible cardiac care across clinical and home environments.

Advantech Corporation is a global leader in embedded computing, industrial automation, edge AI, and intelligent healthcare solutions. The company manufactures industrial-grade computing platforms, edge AI systems, IoT devices, and healthcare-specific IT infrastructure. Product lines include embedded PCs, fanless computers, edge AI and GPU systems, industrial motherboards, medical computers and tablets, medical monitors, and operating room video solutions. Advantech also provides intelligent healthcare platforms (iHospital), medical carts and tablets, and comprehensive design-to-order manufacturing services. The company serves industrial, healthcare, retail, logistics, and transportation sectors with solutions for edge computing, data acquisition, automation control, and healthcare IT infrastructure. Advantech offers design and manufacturing services, global technical support, RMA services, training through IoT Academy, and a comprehensive eStore for procurement. The company emphasizes reliability, industrial-grade specifications, and integration with industry standards.

Element Science, Inc. is a San Francisco-based medical device startup founded in 2013, specializing in clinical-grade wearable solutions for cardiac care. The company's flagship product is the Jewel® Patch Wearable Cardioverter Defibrillator, an adhesive-based patch device designed to treat patients at temporary elevated risk of lethal heart rhythms and sudden cardiac arrest. Unlike traditional bulky defibrillator vests, Jewel® offers a sleek, comfortable, and discreet design that provides 24/7 cardiac monitoring and protection during critical transitions from hospital to home. The device leverages machine learning and data science algorithms to detect and treat dangerous arrhythmias. Element Science has received FDA approval, CE Mark, and UKCA Mark certifications for Jewel®, positioning it as the first and most innovative patch-based wearable cardioverter defibrillator on the market. The company is actively developing a broader pipeline of heart disease solutions that combine wearable technology with predictive analytics to improve patient outcomes and prevent sudden cardiac death.

Medeia Inc is a manufacturer and distributor of neurodiagnostic and cardiovascular physiological monitoring systems. Founded in 1992, the company specializes in state-of-the-art biometric hardware and software for autonomic nervous system assessment, vascular analysis, EEG/EEG-derived diagnostics, and sleep studies. Medeia's product portfolio serves neurologists, cardiologists, primary care physicians, and research institutions with comprehensive tools for objective physiological measurement, including autonomic function testing (ANS), pulse wave velocity analysis, peripheral neuropathy assessment, and neuroencephalography. The VitalScan product line addresses autonomic and vascular diagnostics; BrainView systems provide EEG and cognitive assessment; NeuroTrace offers ambulatory wireless EEG; SleepStudy delivers polysomnography; and CardioView supplies mobile cardiac telemetry. Products are designed for clinical workflow efficiency and are distributed internationally to healthcare providers and research facilities.

LumiQuick Diagnostics Inc. is a minority-owned, privately-held manufacturer of high-quality point-of-care testing and immunoassay kits for the global in vitro diagnostics market. Founded in 2006 and based in Santa Clara, California, the company develops rapid diagnostic tests in multiple formats including test cups, cards, dip tests, and multi-panels. Product lines span infectious disease detection (Dengue, Zika, Chikungunya, COVID-19), drugs of abuse screening, disease markers for cardiac and cancer indicators, fertility hormones, vitamin D assessment, oxidative stress measurement, veterinary diagnostics, food safety testing, and biological threat agent identification. LumiQuick's QuickProfile™ branded assays leverage immunochromatographic technology for qualitative and quantitative detection. The company also manufactures ELISA-based platforms and offers the FDA EUA-cleared Boson Rapid SARS-CoV-2 Antigen Home Test. Products are sold in bulk through local and international distributors, targeting clinical laboratories, point-of-care settings, and compliance screening applications.

Ventric Health manufactures the Vivio® System, an FDA-cleared Class II medical device for non-invasive heart failure diagnosis in primary care settings. The Vivio System uniquely measures left ventricular end-diastolic pressure (LVEDP)—the clinical hallmark of heart failure—using a portable, point-of-care approach combining brachial cuff and ECG technology. The system delivers results in under five minutes and integrates the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) to assess patient symptoms and disease burden. Approximately 70% of patients identified with elevated LVEDP exhibit Stage C heart failure symptoms, while 30% present Stage B findings. The Vivio System demonstrates superior specificity and sensitivity compared to traditional clinical indicators, enabling clinicians to identify at-risk patients earlier and initiate guideline-directed medical therapy more promptly. Target markets include primary care physicians, cardiologists, Medicare ACOs, healthcare systems, and Medicare Advantage plans. The company has established partnerships with leading health systems including Agilon Health, AltaMed, Desert Oasis Healthcare, Heritage Victor Valley Medical Group, and Regal Medical Group. Ventric Health is based in Pasadena, California, and operates through clinical validation studies published in peer-reviewed journals including JACC: Advances and the Journal of the American Heart Association.

Vielight Inc manufactures photobiomodulation (PBM) devices for consumer and clinical use, specializing in transcranial and intranasal light therapy systems targeting brain health and systemic wellness. The company's core technology uses safe, non-ionizing red and near-infrared light energy to stimulate mitochondrial ATP production, with applications in cognitive enhancement, neurological conditions, and immune support. Product lines include the Neuro series (Pro 2, Duo, Gamma, Alpha variants) for brain photobiomodulation targeting Alzheimer's disease, traumatic brain injury, Parkinson's disease, mild cognitive impairment, autism, and PTSD; the Vagus device for non-invasive vagal nerve stimulation; the MIP for systemic wellness and immunity; and the X-Plus for thymus stimulation. Vielight has published 30+ peer-reviewed studies in collaboration with leading institutions including UCSF, Harvard, University of Toronto, Boston University, and University of Utah, with 20+ ongoing clinical trials and 800+ research participants. The company holds Health Canada medical device approval and conducts FDA-regulated clinical studies. Devices are marketed directly to consumers, practitioners, athletes, and military/veteran populations. Manufacturing and logistics are based in Hayward, California; administration in Toronto, Ontario; and a USA sales office in Shepherdstown, West Virginia. Over 100,000 devices sold globally with a 4.8/5 customer rating.

Piccolo Medical designs and manufactures guidance systems for peripherally inserted central catheter (PICC) and central venous catheter (CVC) placement. The company's flagship products—PM2+™ System and ECGuide®—use intravascular electrocardiogram (ECG) technology combined with ionic dilution sensing to enable bedside confirmation of catheter tip positioning, eliminating the need for post-placement chest X-ray confirmation. The PM2+™ System features the Nav+™ stylet with machine learning-powered navigation feedback delivered via a mobile app; setup takes under 90 seconds and provides real-time guidance during catheter insertion. ECGuide® is cleared for use in adult, pediatric, and neonatal patients and has been shown to improve placement accuracy and reduce complications including thrombosis and malposition. The technology addresses a significant clinical and operational problem: approximately 50% of PICCs placed without guidance are malpositioned, requiring confirmatory imaging that adds cost, radiation exposure, and procedure time (average 78-minute wait for chest X-ray). Piccolo Medical is FDA 510(k) cleared and has received funding from the National Institute on Aging (NIA) and other federal agencies. The company serves hospitals and healthcare systems focused on improving catheter placement safety and reducing procedural delays.

Broadata Communications, Inc. (BCI) is a California-based medical device manufacturer specializing in professional AV connectivity and display solutions for healthcare and high-performance environments. Founded in 2000 and ISO 13485 certified, BCI delivers fiber optic video transport systems, HD-BaseT converters, HDMI 4K matrix switches, and medical-grade display technology including 32" 4K surgical displays and wireless monitor stands. The company provides comprehensive design engineering, kitting, and box build manufacturing services for demanding medical applications requiring reliable signal transmission over fiber, IP-based, and coaxial infrastructure. BCI has deployed over 500,000 products globally and serves medical facilities, surgical centers, defense, government, education, and entertainment sectors. Its core competency lies in engineered AV systems integration for operating rooms, diagnostic imaging, and telemedicine environments where signal integrity and compliance are mission-critical.

Boston Scientific Corporation is a global medical device manufacturer serving multiple clinical specialties including cardiology, urology, gastroenterology, interventional radiology, electrophysiology, neurology, pain management, vascular surgery, and structural heart disease. The company manufactures and distributes a broad portfolio of minimally invasive medical devices, including cardiac rhythm management systems, interventional cardiology devices, electrophysiology catheters and mapping systems, spinal cord stimulation systems for pain management, urological devices, endoscopy and visualization systems, defibrillators, and interventional oncology equipment. Boston Scientific operates a healthcare professional portal providing online training through EDUCARE, e-commerce ordering, reimbursement resources, and comprehensive customer support with specialty-specific representative contact networks. The organization serves hospitals, ambulatory surgery centers, and healthcare professionals across the United States through direct sales and support teams organized by medical specialty. Products undergo rigorous regulatory compliance (FDA 510(k), international certifications) and the company emphasizes quality assurance and product safety as core organizational values. Customer care is available via a dedicated U.S. customer service line, with extended business hours Monday–Friday.

PyrAmes Inc develops innovative non-invasive, continuous blood pressure monitoring solutions for patients across all age groups. The company specializes in wireless, calibration-free platforms designed to eliminate the need for invasive arterial lines and improve BP measurement accuracy in critical care settings. Product platforms include: - Boppli®: FDA 510(k)-cleared continuous non-invasive BP monitoring for neonatal and pediatric patients in NICU/PICU environments. Clinical evidence published in peer-reviewed journal Neonatology demonstrates accuracy comparable to arterial lines with superior usability and safety profile. - Bosimi®: Continuous non-invasive BP monitoring system for adult inpatient and emergency department care, enabling real-time hemodynamic assessment without invasive instrumentation. - Bosimi@Home™: Home-based platform for BP diagnostics, treatment validation, and medical management, supporting chronic disease monitoring and hypertension control in ambulatory settings. PyrAmes addresses significant clinical gaps: over 50% of NICU admissions could benefit from continuous BP monitoring but currently receive only intermittent cuff measurements or invasive arterial lines due to cost and safety concerns. In adults, hypertension affects 50% of the US population and contributes to 7.6 million deaths annually worldwide, creating demand for non-invasive continuous monitoring solutions. The company holds FDA 510(k) clearance for Boppli, FDA Breakthrough Device Designation, and recognition from the American Heart Association and National Institutes of Health (NIH RADx Tech Maternal Health Challenge). PyrAmes is a founding member of the CDC National Hypertension Control Roundtable. The technology enables early detection of hemodynamic instability in vulnerable populations including preterm infants and hypertensive adults.

Masimo Corporation is a global leader in noninvasive patient monitoring solutions, specializing in innovative pulse oximetry, vital sign monitoring, and brain function monitoring technologies. Founded on breakthrough accuracy in pulse oximetry (Masimo SET®), the company develops and manufactures continuous monitoring systems for hospitals, ICUs, operating rooms, and neonatal care settings. Core product lines include Masimo SET® Pulse Oximetry for continuous, accurate oxygen saturation measurement across all patient populations and clinical settings; SedLine® Brain Function Monitoring for depth-of-anesthesia and sedation monitoring; Masimo O3® Regional Oximetry for tissue oxygenation assessment with FDA-cleared hemoglobin parameters; and Root® Patient Monitoring and Connectivity Platform, a modular hospital automation system integrating vital signs, connectivity, and clinical workflow solutions. Masimo technologies are deployed across acute care, perioperative, emergency, neonatal, and general floor environments. The company holds over 900 patents globally and serves leading hospitals and healthcare systems in 30+ countries. Known for motion-artifact rejection and performance accuracy across diverse patient populations, Masimo's solutions address clinical needs in congenital heart disease screening, critical care monitoring, anesthesia management, and cost reduction through early patient distress detection. The company emphasizes sustainability and has strategic partnerships with major healthcare technology providers including Philips. Acquired by Danaher in February 2026.

Thirdwayv is an IoT connectivity and cybersecurity software company specializing in secure, connected medical devices and healthcare applications. The company provides end-to-end security solutions—from hardware root of trust through cloud infrastructure—for safety-critical IoT deployments in consumer medical devices, connected hospitals, home healthcare, electrical stimulation and drug delivery systems, and biometric monitoring. Core product lines include AppAuth™ (device and customer authentication, remote attestation), SecureConnectivity™ (application-layer encryption across Bluetooth, NFC, LTE, Ethernet), SeamlessConnect™ (seamless device-to-gateway connectivity), and RecordAuth™ (blockchain-based data authenticity for supply chains). Thirdwayv holds FDA clearances enabling partners to meet FDA cybersecurity guidelines for medical devices and has demonstrated expertise in connected diabetes management, pacemakers, nerve stimulators, defibrillators, insulin pumps, thermometers, blood pressure monitors, glucose meters, and pulse oximeters. The company also serves connected car (OTA firmware updates, infotainment security, smartphone keyless entry) and asset-tracking markets (cold chain, surgical implant track-and-trace, hospital inventory management, retail item tracking). Leadership includes executives from Motorola, Broadcom, and GE; the advisory board includes former Qualcomm, Google, BlackBerry, and FDA officials. Thirdwayv positions itself as a "nucleus of trust" for IoT ecosystems, emphasizing security-by-design from the semiconductor level upward.

Bodyport Inc. is a biomarker-guided digital therapeutics company specializing in remote monitoring solutions for complex chronic conditions, particularly heart failure. The company's FDA-cleared Bodyport Cardiac Scale (Fluiditi™) is a non-invasive, at-home device that measures hemodynamic biomarkers—including heart function and fluid status—through advanced sensors embedded in a bathroom scale. Patients simply step on the device for under 30 seconds, and data transmits via cellular connection to care teams within minutes. The proprietary Congestion Index algorithm combines multiple hemodynamic biomarkers into a composite metric for early detection of worsening heart failure, demonstrating superior performance over traditional weight-based monitoring in clinical validation. Bodyport's integrated care platform combines a clinical portal with a patient app, delivering actionable insights for timely clinician interventions. The system supports RPM billing, integrates via API with leading EHRs, and maintains HIPAA compliance and SOC 2 certification. The company partners with major health systems including Geisinger, Stanford, Duke, and Brigham & Women's Hospital, backed by peer-reviewed clinical evidence published in leading medical journals.

DWL (Compumedics Germany GmbH), operating since 1991, is a specialized manufacturer of transcranial Doppler (TCD) ultrasound systems for real-time hemodynamic monitoring and vascular diagnostics. Core products include the EZ-Dop point-of-care diagnostic system, Multi-Dop T (EU MDR 2017/745 certified), DBX/DBX1, MDX series (color Doppler and CO2 reactivity), and the MDT multi-channel monitoring platform. The company designs portable baseline systems through comprehensive multimodal solutions supporting handheld probes, micro-probes, monitoring probes, probe fixation systems, and specialized analysis software including Neuro-Monitoring-Analyse with Z-Score waveform evaluation. Clinical applications span neurology, neuro/cardiac/vascular surgery, anesthesiology, critical care, emergency medicine, ENT, and maxillofacial surgery. Primary indications include stroke management, brain death diagnosis, vasospasm detection, PFO evaluation, sickle cell disease screening, and intraoperative neuromonitoring. Systems employ fully digital Doppler sonography with M-Mode capability. DWL maintains installations in 11,000+ hospitals and clinics across 120+ countries. Manufacturing and regulatory capabilities include EU MDR compliance and ISO certification. The company provides clinical software, training support at international conferences, and technical service.

Vektor Medical develops vMap, an FDA-cleared and CE-marked arrhythmia analysis software platform that uses artificial intelligence to extract diagnostic insights from standard 12-lead ECGs. vMap provides non-invasive, four-chamber cardiac mapping and analysis for seven arrhythmia types, including atrial fibrillation, atrial and ventricular tachycardia, ventricular fibrillation, pacing, premature atrial and ventricular complexes (PACs and PVCs), and orthodromic atrioventricular reentrant tachycardia. The software is designed to integrate into current cardiac ablation workflows, improving procedural outcomes and efficiency for electrophysiologists and cardiac care teams. vMap addresses a significant clinical need in arrhythmia management; arrhythmias account for approximately 10% of global deaths, and over 25% of adults over age 40 develop serious arrhythmias. The company is based in San Diego and was recognized as UC San Diego Chancellor's Innovation Awards Startup of the Year in 2024. Regulatory status: FDA 510(k) clearance and CE mark.

Rhythm AI Inc develops software-based diagnostic and decision-support solutions for cardiac electrophysiology. The company's flagship product, STAR Apollo Mapping System, is an AI-enabled software platform designed to analyze real-time data from existing electrophysiology (EP) systems for the treatment of atrial fibrillation (AF). STAR Apollo uses proprietary algorithms based on electrophysiological principles to identify repetitive patterns of activation (RPAs) and early sites of activation (ESAs) within arrhythmias, enabling electrophysiologists to locate potential AF drivers and develop individualized ablation strategies. The system integrates into current EP lab workflows without requiring new hardware infrastructure, allowing physicians to create personalized treatment plans based on comprehensive rhythm analysis. The technology targets hospital and specialty cardiology centers performing catheter ablation and electrophysiological mapping procedures.